IONS - アイオニス・ファ―マシュ―ティカルズ (Ionis Pharmaceuticals Inc.)

IONSのニュース

   RNA Therapeutics Market 2020 Analysis, Size, Share, Growth, Trends And Forecast, Leading Players are Quark, Sanofi, Ionis Pharmaceuticals, Silence Therapeutics, Cenix BioScience, Marina Biotech  2020/10/14 15:12:51 OpenPR
The winning RNA Therapeutics Market report makes available the current and forthcoming technical and financial details of the industry. Few of the chief insights of this business report include; distinct analysis of the market drivers & restraints, major market players
   Ionis' inhaled antisense medicine demonstrates potential as a novel treatment for cystic fibrosis  2020/10/13 11:05:00 PR Newswire
CARLSBAD, Calif., Oct. 13, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, announced today that data from a clinical trial of IONIS-ENAC-2.5Rx demonstrated a significant decrease in the expression of epithelial sodium channel (ENaC)…
   Ionis Pharmaceuticals completes acquisition of Akcea Therapeutics  2020/10/12 13:00:00 PR Newswire
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the successful completion of its transaction to acquire 100% ownership of Akcea…
   Aro Collaboration with Ionis Advances with Option Exercise  2020/10/06 12:00:00 Business Wire
PHILADELPHIA--(BUSINESS WIRE)--Aro Biotherapeutics, a biotechnology company focused on developing a new generation of medicines based on its proprietary CENTYRIN™ technology, announced today that Ionis Pharmaceuticals, Inc., the leader in RNA-targeted therapeutics, has exercised an option to acquire a license to an undisclosed antisense oligonucleotide (ASO)-Centyrin drug conjugate. In December 2019, Aro and Ionis entered into a licensing and collaboration agreement to advance a defined number
   Ionis Chief Scientific Officer Frank Bennett receives Lifetime Achievement Award from Oligonucleotide Therapeutics Society  2020/10/01 20:05:00 PR Newswire
CARLSBAD, Calif., Oct. 1, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, announced today that Frank Bennett, Ph.D., Ionis' executive vice president and chief scientific officer, has been awarded the 2020 Lifetime Achievement Award by…
   AKCEA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akcea Therapeutics, Inc. - AKCA  2020/09/04 23:49:00 Business Wire
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Akcea Therapeutics, Inc. (NasdaqGS: AKCA) to Ionis Pharmaceuticals, Inc. (NasdaqGS: IONS). Under the terms of the proposed transaction, shareholders of Akcea will receive only $18.15 in cash for each share of Akcea that they own. KSF is seeking to determine whether this consideration and the process that led t
   Ionis to present at upcoming virtual investor conferences  2020/09/03 11:05:00 PR Newswire
CARLSBAD, Calif., Sept. 3, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in antisense therapeutics, today announced that management will present a company overview at the following virtual investor conferences: Wells Fargo 2020 Healthcare Conference on…
   INVESTOR ALERT: Monteverde & Associates PC Announces an Investigation of Akcea Therapeutics, Inc. - AKCA  2020/09/01 21:05:00 Benzinga
NEW YORK , Sept. 1, 2020 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City , is investigating Akcea Therapeutics, Inc. ("Akcea" or the "Company") (Nasdaq: AKCA) relating to its sale to Ionis Pharmaceuticals, Inc. Under the terms of the agreement, Akcea shareholders will receive $18.15 in cash for each share of Akcea common stock owned. … Full story available on Benzinga.com
   Akcea Therapeutics Rallies After Majority Owner Ionis Agrees To Buy Remaining Stake  2020/08/31 14:26:58 Benzinga
Akcea Therapeutics Inc (NASDAQ: AKCA ) shares were rallying strongly Monday following a buyout deal. The Ionis, Akcea Deal Terms: Akcea and its majority owner Ionis Pharmaceuticals Inc (NASDAQ: IONS ) announced a definitive agreement under which Ionis will acquire the 24% stake in Akcea it does not already own for $18.15 per share — about 60% higher than Akcea's Friday closing price. The total transaction value is about $500 million. The deal has been approved by the boards of both companies and … Full story available on Benzinga.com
   Ionis Pharmaceuticals to hold cardio-renal franchise webcast  2020/08/26 11:05:00 PR Newswire
CARLSBAD, Calif., Aug. 26, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, September 2nd at 10:00 a.m. Eastern Time to review its cardio-renal franchise. The approximately 90-minute webcast will include…
   Ionis Pharmaceuticals to hold cardio-renal franchise webcast  2020/08/26 11:05:00 PR Newswire
CARLSBAD, Calif., Aug. 26, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, September 2nd at 10:00 a.m. Eastern Time to review its cardio-renal franchise. The approximately 90-minute webcast will include…
   Earnings Scheduled For August 5, 2020  2020/08/05 08:20:31 Benzinga
Companies Reporting Before The Bell • AmerisourceBergen Inc. (NYSE: ABC ) is expected to report quarterly earnings at $1.56 per share on revenue of $44.66 billion. • Advanced Energy Indus Inc. (NASDAQ: AEIS ) is expected to report quarterly earnings at $0.81 per share on revenue of $318.21 million, • ALLETE Inc. (NYSE: ALE ) is expected to report quarterly earnings at $0.67 per share on revenue of $290.75 million. • Allogene Therapeutics Inc. (NASDAQ: ALLO ) is expected to report earnings for its second quarter. • Ares Management Inc. (NYSE: ARES ) is estimated to report quarterly earnings at $0.38 per share on revenue of $343.00 million. • Astec Industries Inc. (NASDAQ: ASTE ) is estimated to report quarterly earnings at $0.05 per share on revenue of $228.97 million. • Athene Holding Inc. (NYSE: ATH ) is estimated to report quarterly earnings at $1.71 per share on revenue of $1.00 billion. • Axcella Health Inc. (NASDAQ: AXLA ) is expected to report earnings for its second quarter. • Brainstorm Cell Inc.
   Ionis Pharmaceuticals to hold second quarter 2020 financial results webcast  2020/07/22 11:05:00 PR Newswire
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, August 5th at 11:30 a.m. Eastern Time…
   Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Misses Revenue Estimates  2020/05/06 13:45:05 Zacks Investment Research
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 9.09% and -16.90%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
   Earnings Preview: Ionis Pharmaceuticals (IONS) Q1 Earnings Expected to Decline  2020/04/29 16:34:40 Zacks Investment Research
Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

calendar